VANCOUVER, June 12, 2015 /CNW/ – ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. All shares of common stock to be sold in the offering will be offered by ProNAi. The number of shares to be offered and the price range for the proposed offering have not yet been determined. ProNAi intends to list its common stock on the NASDAQ Global Market under the ticker symbol “DNAI.”
Jefferies LLC and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering. BofA Merrill Lynch is also serving as ProNAi’s strategic IPO advisor. Wedbush PacGrow and SunTrust Robinson Humphrey are acting as co-managers. This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, email: Prospectus_Department@Jefferies.com; or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, by telephone at (866) 500-5408, or by email at dg.prospectus_requests@baml.com. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. SOURCE ProNAi Therapeutics Inc. For further information: James Smith, Vice President, Corporate Affairs, ProNAi Therapeutics, 604.558.6545, jsmith@pronai.com This information is being distributed to you by / Cette information vous est transmise par : ProNAi Therapeutics Inc. 2150 – 885 West Georgia St., Vancouver, BC V6C 3E8 http://pronai.com/ This entry was posted in ProNAi. Bookmark the permalink.
0 Comments
KALAMAZOO, Mich., May 13, 2015 /PRNewswire/ — Ablative Solutions, Inc. (ASI), a venture-backed, privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, today announced that it has received the CE Certificate of Conformity allowing ASI to apply the CE Mark to the Peregrine SystemTM Infusion Catheter. This will enable the Peregrine System to be used to treat hypertensive patients in Europe with the infusion of a neurolytic agent into the perivascular space surrounding the renal artery, targeting the sympathetic nerves that contribute to hypertension. This targeted approach offers physicians a new tool to help manage patients with high blood pressure.
Ablative Solutions is currently enrolling patients in the European Peregrine clinical trial for drug-resistant hypertension. The Principal Investigator of the study, Prof. Wojtek Wojakowski, stated: “I have had the opportunity to be one of the first users of the Peregrine System Infusion Catheter in Europe. Early results suggest that perivascular alcohol denervation is a promising approach. I’m impressed by how simple and rapid the procedure is with this technology. The procedures I have performed take only about 15 minutes and have been performed under mild or no sedation, without the need for an anesthesiologist, thereby enabling same-day discharge.” This clinical study will continue to enroll and follow patients to confirm the safety and the clinical benefits associated with use of the device. “This is a major milestone for ASI, and comes at a time when there is a great need to address uncontrolled hypertension, a significant disease which affects millions of patients,” said Jon H. Hoem, President of Ablative Solutions Europe. “We’ve learned from previous clinical trials that effectively interrupting the sympathetic nerve signals can reduce blood pressure. A key advantage of the Peregrine System is that it infuses the ablative therapy directly into the perivascular region, where the nerves reside, and provides deep and circumferential distribution, which we believe will result in a more efficient denervation. We look forward to working with European clinicians to document the full potential of ASI’s technology.” Ablative Solutions plans to initiate a post-market study in Europe to gather additional clinical and health-economic data in support of commercialization. The Company is also in the planning stage of a randomized clinical trial in the US to support marketing permission for the treatment of hypertension. In the US, the Peregrine System has received 510(k) clearance as a tool for the infusion of diagnostic and therapeutic agents into the perivascular area of the peripheral vasculature; however, it remains investigational for the treatment of hypertension. Ablative Solutions, Inc. was founded by two proven medical device entrepreneurs, Tim Fischell, M.D., and David Fischell, PhD. Product development efforts have been led by ASI President & COO, Vartan Ghazarossian, PhD, whose executive experience in both biopharmaceutical and medical device companies has added significant value to this novel therapeutic approach to hypertension. Forward-Looking Statements Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of ASI’s products to patients, market and physician acceptance of ASI’s products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. ASI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information: Vartan Ghazarossian, PhD President (650) 321-6884 http://www.ablativesolutions.com Logo – http://photos.prnewswire.com/prnh/20150513/215783LOGO SOURCE Ablative Solutions, Inc. This entry was posted in Ablative Solutions. Bookmark the permalink. Vestaron has received expanded EPA registration for its biological insect control products. These innovative bioinsecticides, which are derived from newly discovered naturally occurring peptides, will be commercially available later this year under the Spear trade name. The new registration represents a significant expansion of crops and insects covered. Included are caterpillars (Lepidoptera), beetles (Coleoptera), and thrips (Thysanoptera). Scientific data for bee and other beneficial insect safety are very encouraging.
“The approval of this expanded label represents a significant milestone in our pursuit of successful commercialization of this highly efficacious and environmental friendly technology. It’s truly an exciting time for Vestaron,” says Mark Quick, VP of Business Development and Marketing. “Insect resistance to existing chemistries is a huge concern. Vestaron’s products with their unique mode of action and outstanding safety profile provides growers with a new and effective option for control of target pests. They will be a prime choice in resistance management programs, while providing growers greater flexibility in field operations. The aim is delivering high quality crops that meet the demands of food retailers and consumers,” Quick said. “Our immediate focus is to greatly expand field testing and demonstration trials so growers have the opportunity to see the value of this new technology first hand.” This entry was posted in Vestaron. Bookmark the permalink. FENTON, Mich., April 8, 2015 /PRNewswire/ — Burgaflex North America, a leading manufacturer of coolant system tube and hose assemblies serving the heavy truck, agricultural and off-road markets, today announced the acquisition of Burgaflex GmbH, a Germany-based supplier of tube and hose assemblies for the heavy truck, bus, construction and agricultural equipment industries.
Founded in 2001, Burgaflex GmbH currently employs 45 people and anticipates the company growing to more than 60 employees over the next five years as a result of this transaction. The company operates out of its 25,000-square-foot facility and predominantly serves the aftermarket. “Burgaflex NA and Burgaflex GmbH were both previously part of the Burgaflex Group, which disbanded in 2010. Now, five years later, the companies are reunited and stronger than ever,” said David Kennedy, CEO of Burgaflex NA. “Our team has a strong relationship with Burgaflex GmbH, which will make for a smooth transition and integration of the two businesses.” The transaction marks the first international acquisition for Burgaflex NA, and will provide them with a key European location to help better service their global OEM customer base. “In approaching this acquisition, we factored in the strategic importance of international business,” said Jeremy Sheppard, President of Burgaflex NA. “We are confident that we can aggressively grow the business and improve the profitability through an increased focus on both operational efficiency and systems integration.” Blackford Capital, a Grand Rapids, Mich.-based private equity firm who partnered with Burgaflex NA in July of 2014, helped facilitate the acquisition. Both parties are excited about the company’s anticipated growth and international exposure. “International expansion is a fundamental component of the Burgaflex NA growth strategy, and we expect to see continued synergies as the two companies begin to fully integrate,” said Martin Stein, Managing Director of Blackford Capital and Chairman of Burgaflex NA. “We are eager to move forward with the acquisition, and believe this transaction will help strengthen the business and better serve our customers.” About Blackford Capital Blackford Capital is a private equity firm based in Grand Rapids, Mich., that acquires, manages and builds middle-market manufacturing, distribution and service companies, with seven portfolio companies across the country. Blackford reviewed roughly 4,813 transactions in 2014, and has closed 33 transactions in the past seven years. The firm’s investment criteria includes mature, profitable businesses with revenues between $20 million and $100 million, with management teams that are either willing to remain with the company or are seeking to retire. For more information, visit www.blackfordcapital.com. About Burgaflex NA Burgaflex NA is a leading manufacturer of tube and hose assemblies for the heavy truck and agriculture markets. Since 2004, Burgaflex NA has been meeting the growing needs of a diverse range of customers by focusing on manufacturing quality products at competitive prices. For more information, visit www.burgaflexna.com. To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/blackford-capitals-burgaflex-north-america-acquires-burgaflex-gmbh-300062421.html SOURCE Blackford Capital This entry was posted in BurgaFlex. Bookmark the permalink. Applying subthreshold voltage technology to real-time clocks changes the MCU power equation3/24/2015 A basic hardware building block in any embedded developer’s repertoire of low power design aids is the lowly real-time clock (RTC). In its simplest form, the function of an RTC is to keep track of the current time. But the RTC has taken on a pivotal role as the means by which to monitor and manage sparse power resources in almost any untethered embedded or Internet of Things design.So it should come as no surprise that almost every maker of microprocessors and microcontrollers also provides at least one RTC circuit in its catalog of products, including most of the major makers of ARM-based processors and SoCs, including NXP Semiconductor, Silicon Labs, and ST Microelectronics. The reason is simple: developers still have to deal with the power requirements of the rest of the components in a design.
Ambiq Micro has addressed this challenge by using the Subthreshold Power Optimized Technology (SPOT) used in its Apollo family of ARM Cortex-M4F MCUs to also fabricate its AM08XX/18XX real time clock family (Figure 1), now in volume production. In an interview with EE Times, Ambiq Vice President of Marketing Mike Salas said that as a result of the incorporation of SPOT, developers using Ambiq RTCs can reduce the power consumption of any component in a design 10-fold, including the MCU/MPU. He said the company’s tests indicate that using one of its subthreshold voltage-based RTCs in a system will reduce current — and thus power consumption — to no more than 55 nano-amperes with an external crystal, 15 nA with a standard resistor–capacitor circuit (RC circuit), or 21 nA using an auto-calibrated RC. “The RTCs we have built allow the design of systems that are roughly seven times lower in power than the NXP PCS 2123 RTC, and at least 10 times lower than similar devices from Integrated Device Technology, Maxim, and STMicroelectronics,” he said.(Figure 2). And because they are processor agnostic, Ambiq’s RTCs can reduce the power consumption of any embedded system design based on any processor, including high end ARM, MIPS, and Intel Atom-based 32- or 64-bit CPUs as well as any 8- or 16-bit microcontroller. If these claims are proven in working designs, the near-term impact of Ambiq’s RTC family is more far-reaching than the use of its subthreshold voltage technology in 32-bit processor designs. The shift to threshold voltage-based RTCs will make any 32-bit MCU more viable in power constrained IoT designs. But at the same time, it will make already low power 8- and 16-bit MCUs even more so, considerably extending their operational life, especially in applications that require unattended operation over months or years using only batteries or energy harvesting. The AM08XX/18XX devices achieve this power savings in a number of ways, Salas said. First, operating purely as real time clocks, they drastically reduce the independent battery-backup requirements that any RTC has to depend on to provide timing and power management functions to the rest of the system. “Despite the fact that they play a key role in managing MCU design power resources, traditional RTCs are incredibly power-hungry,” he said. “Because our RTCs draw seven to 10 times less current, they can operate using less expensive and commodity type coin cells and cheaper ceramic capacitors, which only cost a few cents, instead of more expensive super-capacitors.” Second, to extend the subthreshold-based power savings to the rest of the system, the AM08XX/18XX family of devices can be configured in a variety of system implementations to control the power used by other elements in the system (Figure 3). The most common use of an Ambiq RTC is to manage the VCC power switch that completely turns off the MCU and/or other system elements. But to provide the MCU system designer additional flexibility, Ambiq’s RTCs can also be reset- or interrupt-driven. The key benefit of using an AM08XX/18XX device in the recommended VSS power switched mode (Figure 4) is that in addition to putting the MCU – or any other components similarly configured – asleep, it can be used to wake up the MCU or other logic with any number of triggers: a simple predetermined alarm, via a countdown timer to wake it up periodically, or by an externally operated manual input, such as a push button or switch. It can also be triggered by a range of external device and analog inputs, such as light sensors or radio antenna detectors, when the battery is low, or when any interrupt failure occurs. Because the AM08XX/18XX family is based on an RTC circuit originally developed as a means by which to test Ambiq’s proprietary nanometer CMOS SPOT enhancements, they are fabricated with an 0.18 millimeter (180 nm) process, leaving considerable IC silicon real estate for additional features, versus the much more conservative geometries used in most competitive RTCs. “This means we were able to integrate a wide range of power management functions not normally included in a real time clock circuits,” said Salas, “including power switch management, system sleep, automatic battery switchover, analog voltage comparator monitoring, reset and trickle charge management.” These additional on-chip features make them viable in a range of use cases where a traditional RTC alone cannot be considered without additional external logic. For example, using an external power switch feature built into the design, an Ambiq RTC can be used to switch an MCU-based design to an alternative backup power resource. Alternatively, it could be used in combination with other power management functions to power gate on and off a variety of external system functions, including other MCUs, displays, or radio systems. “In energy harvesting designs, which often use a rechargeable battery or a super-capacitor to store energy for later use, our RTCs’ trickle charge feature would allow collection of energy at much lower voltage and current levels, as well as manage the storage of such resources, and when to use them.” Bottom line, said Salas, the fundamental advantage provided by the company’s AM08XX/18XX RTCs is that they allow the system designer to ignore the sleep current of other system components, allowing the use of components which under ordinary circumstances would have to be optimized using other less efficient parameters. — Bernard Cole, MCU and PCB Designline editor,EE Times is an embedded microsystems technology analyst who writes about hardware/software design and use across the range of consumer, industrial, automotive, networking and Internet of Things applications. He can be contacted via LinkedIn, by email at bccole@techrite-associates.com, or at 928-525-9087. Posted in Ambiq Micro |
TROUT CREEK VENTUResA regional co-investment fund specializing in angel and early stage private equity. Archives
June 2017
Categories |